Table of Contents
Josh Michelson has started serving as executive vice president and chief strategy officer, also holding the title of chief innovation officer, according to a recent LinkedIn post. The appointment places Michelson in one of the company’s most strategically significant leadership roles, overseeing how the company approaches long-term growth and corporate innovation going forward.
What the Cigna Chief Strategy Officer Role Involves
A website said Michelson, as chief strategy officer, is responsible for steering the company’s long-term strategic direction, corporate innovation, and The Group Ventures, the company’s venture capital branch. This combination of responsibilities positions him at the intersection of strategic planning and forward-looking investment activity within the organization.
Overseeing The Cigna Group Ventures
As part of his role, Michelson’s oversight of The Group Ventures gives him direct influence over how the company identifies and invests in emerging healthcare innovations, an area that has become increasingly important for large payers looking to diversify beyond traditional insurance offerings.
Michelson’s Path to Cigna Chief Strategy Officer
Michelson joined in 2020 and was most recently a senior vice president and chief strategy and transformation officer for the company before stepping into his new role as chief strategy officer. His trajectory within reflects a steady progression through strategy-focused leadership positions over roughly five years with the organization.
A Background in Management Consulting
Prior to his tenure, Michelson was a senior partner at consulting firm Oliver Wyman, giving him a strong foundation in strategic advisory work before transitioning into an internal leadership role. That consulting background likely shaped how he approaches the strategic and innovation mandate now attached to his position as chief strategy officer.
What This Appointment Signals for Cigna
Michelson’s elevation to chief strategy officer comes amid broader leadership changes at the company, following Brian Evanko’s transition to CEO on July 1. The timing suggests the company is continuing to reshape its executive team as it moves into a new chapter under new top leadership, with strategy and innovation roles playing a prominent part in that transition.
What to Watch Going Forward
As chief strategy officer, Michelson’s decisions around The Group Ventures and broader corporate innovation efforts will likely shape how the company positions itself competitively in the coming years, particularly as health insurers continue exploring diversification beyond core insurance products.
A Broader Pattern of Strategy-Focused Leadership in Payers
Michelson’s appointment as chief strategy officer also reflects a broader trend among large health insurers, who have increasingly elevated dedicated strategy and innovation executives to sit alongside traditional financial and operational leadership. As payers face mounting pressure from rising medical costs, shifting regulatory requirements, and growing competition from tech-enabled healthcare entrants, having a senior leader focused specifically on long-term positioning and venture investment has become a more common structural response across the industry, not just at the company.
How This Compares to Peer Payer Strategy Roles
The structure, pairing a dedicated chief strategy officer with an internal venture arm, mirrors similar moves at other major insurers that have created parallel innovation and venture functions in recent years. Other major insurers’ venture investments follow a comparable logic: rather than relying solely on internal R&D or one-off partnerships, large payers are building dedicated capital vehicles to identify and invest in promising healthcare startups early.
Michelson’s dual mandate over strategy and venture investment suggests the company intends to keep these functions closely integrated rather than operating them as separate silos, a structural choice that could shape how quickly it moves on emerging opportunities compared to peers with more fragmented strategy and investment teams.
